Allergies news and allergies widget

Breakthrough: Results from the fourth year in a long-term clinical study prove the disease modifying effect of GRAZAX(R). For the first time ever, it is documented that the positive clinical effect of the tablet vaccine persists after completion of treatment. Today, ALK announces main results from the first follow-up year in a long-term study (GT-08) with GRAZAX(R), the company's tablet-based vaccine against grass pollen allergy.

Title: health Tip: Help Prevent NosebleedsCategory: health newscreated: 10/23/2008 2:00:00 amlast Editorial review: 10/23/2008